of colipase and angiogenin-3 mRNAs in these ex-germ-free mice were comparable to those of age-matched mice conventionally raised since birth (Fig. 2) . In contrast, the response of sprr2a to colonization depended on the colonizing species: B. infantis and E. coli produced only small increases (Fig. 2 ). Mdr1a and glutathione S-transferase also exhibited species-specific responses. Bacteroides thetaiotaomicron suppressed and E. coli and B. infantis stimulated expression of both genes, whereas the multicomponent ileal/cecal flora produced no significant (i.e., Նtwofold) change in levels of either mRNA compared with germ-free controls. The differing Mdr1a/GST responses suggest that variations in xenobiotic metabolism between individuals may arise, in part, from differences in their resident gut flora.
The only B. thetaiotaomicron genes currently known to link changes in bacterial metabolism with host responses are those involved in fucose utilization (3) . Transposon-mediated mutagenesis of fucI (encoding fucose isomerase) blocks the organism's ability to use fucose as a carbon source and to signal fucosylated glycan production in the ileal epithelium (3) . Microarray analysis of the host response to colonization revealed no appreciable differences between isogenic mutant and wild-type strains. This similarity extends to all genes in Table 1 . Future identification of microbial factors that interlink microbial and host physiology will require characterization of changes in B. thetaiotaomicron gene expression as a function of colonization.
In summary, the studies described above provide a broad-based in vivo characterization of transcriptional responses to colonization with a prototypic gut commensal. Our results reveal that commensals are able to modulate expression of host genes that participate in diverse and fundamental physiological functions. The species selectivity of some of the colonization-associated changes in gene expression emphasizes how our physiology can be affected by changes in the composition of our indigenous microflora. The fusion of germ-free technology, functional genomics, and LCM/qRT-PCR makes it possible to use in vivo systems to quantify the impact of a microbial population on host cell gene expression.
Protein Design of an HIV-1 Entry Inhibitor
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Human immunodeficiency virus type-1 (HIV-1) membrane fusion is promoted by the formation of a trimer-of-hairpins structure that brings the amino-and carboxyl-terminal regions of the gp41 envelope glycoprotein ectodomain into close proximity. Peptides derived from the carboxyl-terminal region (called C-peptides) potently inhibit HIV-1 entry by binding to the gp41 amino-terminal region. To test the converse of this inhibitory strategy, we designed a small protein, denoted 5-Helix, that binds the C-peptide region of gp41. The 5-Helix protein displays potent (nanomolar) inhibitory activity against diverse HIV-1 variants and may serve as the basis for a new class of antiviral agents. The inhibitory activity of 5-Helix also suggests a strategy for generating an HIV-1 neutralizing antibody response that targets the carboxyl-terminal region of the gp41 ectodomain.
Infection by HIV-1, the virus that causes AIDS, requires fusion of the viral and cellular membranes (1) (2) (3) . This membrane-fusion process is mediated by the viral envelope glycoprotein complex (gp120/gp41) and receptors on the target cell. Binding of gp120/ gp41 to cell-surface receptors (CD4 and a coreceptor, such as CCR5 or CXCR4) triggers a series of conformational changes in the gp120/gp41 oligomer that ultimately lead to formation of a trimer-of-hairpins structure in gp41 (Fig. 1A) . The trimer-of-hairpins is a common structural element involved in the fusion process of many enveloped viruses, suggesting a critical role for this motif in promoting mem-brane fusion (3) (4) (5) . In HIV-1 gp41, the core of the trimer-of-hairpins is a bundle of six ␣-helices (Fig. 1B) : three ␣-helices (formed by the COOH-terminal regions of three gp41 ectodomains) pack in an antiparallel manner against a central, three-stranded coiled coil (formed by the NH 2 -terminal regions of the gp41 molecules) (6) (7) (8) (9) . The fusion peptide region, which inserts into the cellular membrane, is located at the extreme NH 2 -terminus of gp41, and the COOH-terminal region is adjacent to the transmembrane helix anchored in the viral membrane. Thus, the trimer-of-hairpins motif brings the two membranes together (Fig. 1A) .
Agents that interfere with formation of the gp41 trimer-of-hairpins structure can inhibit HIV-1 infection. Peptides derived from the COOH-terminal region of the gp41 ectodomain, referred to as C-peptides (corresponding to the outer helices of the six-helix bundle), are effective inhibitors of HIV-1 infection (10) (11) (12) . Studies from several groups support a mechanism of dominant-negative inhibition in which C-peptides bind to a transient gp41 species known as the prehairpin intermediate (Fig. 1A) (1, 6, (12) (13) (14) (15) . In this prehairpin intermediate, the gp41 fusion peptide is embedded in the target-cell membrane, exposing the NH 2 -terminal three-stranded coiled coil [compare (16) ]. Binding of Cpeptides to the NH 2 -terminal region of the prehairpin structure prevents formation of the gp41 trimer-of-hairpins, ultimately leading to irreversible loss of membrane-fusion activity. C-peptides potently inhibit HIV-1 entry, with a mean inhibitory concentration (IC 50 ) as low as 1 nM in vitro (11, 12) . One such C-peptide is in clinical trials and shows antiviral activity in humans (2, 17) . More recently, efforts to target a prominent pocket on the surface of the NH 2 -terminal coiled coil of the prehairpin intermediate have led to the discovery of small, cyclic D-peptides that inhibit HIV-1 infection, thereby validating the pocket as a potential target for development of small, orally bioavailable HIV-1 entry inhibitors (18) .
The importance of trimer-of-hairpins formation for HIV-1 entry leads to the hypothesis that the COOH-terminal region on gp41 might also serve as a target for potential membrane-fusion inhibitors (Fig. 1A) . If the COOH-terminal region is accessible (at least transiently) before formation of the trimer-ofhairpins, then agents that bind to this region of gp41 may prevent fusion. Consistent with this notion (6), peptides derived from the gp41 NH 2 -terminal region (referred to as Npeptides) are modest inhibitors of HIV-1 membrane fusion (micromolar IC 50 ) (6, 19) . The inhibitory mechanism of N-peptides, however, has not been ascertained, in part because these peptides have a strong tendency to aggregate. Indeed, a plausible alternative mechanism of action for the N-peptides is that they intercalate into the gp41 NH 2 -terminal coiled coil, thereby disrupting the trimeric interface (19, 20) .
To directly test the hypothesis that the C-peptide region of gp41 is a potential target for the inhibition of HIV-1 entry, we designed a protein that binds tightly and specifically to this site. The design takes advantage of the binding properties of the N-peptide coiled coil while minimizing the tendency of the N-peptides to aggregate. In this designed protein, denoted 5-Helix, five of the six helices that make up the core of the gp41 trimerof-hairpins structure are connected with short peptide linkers (Fig. 1C) (21) . The 5-Helix protein lacks a third C-peptide helix, and this vacancy is expected to create a high-affinity binding site for the COOH-terminal region of gp41.
Under physiological conditions, 5-Helix is well folded, soluble, and extremely stable, with an ␣-helical content in close agreement with the value predicted from the design (Fig.  2, A and B) . In affinity-interaction experiments, 5-Helix interacts strongly and specifically with epitope-tagged C-peptides (Fig.  2C) . Moreover, this interaction induces a helical conformation in the bound C-peptide, as judged by the difference in circular dichroism (CD) before and after mixing (Fig. 2D) . These properties are consistent with the intended design of 5-Helix.
The 5-Helix protein potently inhibits HIV-1 membrane fusion (nanomolar IC 50 ), as measured by viral infectivity and cell-cell fusion assays (Fig. 3, A and B) . In contrast, a control protein, denoted 6-Helix, in which the C-peptide binding site is occupied by an attached C-peptide (i.e., all six helices that constitute the gp41 trimer-of-hairpins have been linked into a single polypeptide) (21, 22) , does not have appreciable inhibitory activity (Fig. 3A) denoted 5-Helix(D4), in which the C-peptide binding site is disrupted by mutation of four interface residues (V549, L556, Q563, and V570) to Asp (23), does not block membrane fusion even at 1 M (Fig. 3A) . We conclude that C-peptide binding is the key determinant of antiviral activity in 5-Helix.
The inhibitory activities of 5-Helix and C-peptides are expected to be antagonistic: when 5-Helix binds C-peptide, the amino acid residues thought to be responsible for the antiviral activities of each inhibitor are buried in the binding interface. Indeed, mixtures of 5-Helix and C34 [a well-characterized and potent C-peptide inhibitor with an IC 50 Ϸ 1 nM (12)] display a dose-dependent antagonistic effect (Fig. 3B) . In the presence of 5-Helix, high-potency inhibition by C34 is only observed when the peptide is in stoichiometric excess (Fig. 3B) .
The 5-Helix protein inhibits infection by viruses pseudotyped with a variety of HIV-1 envelope proteins (from clades A, B, and D) with similar potency (Fig. 3C ). This broadspectrum inhibition likely reflects the highly conserved interface between the NH 2 -and COOH-terminal regions within the gp41 trimer-of-hairpins structure (Fig. 4) . The residues in the C-peptide region of gp41 that are expected to make contact with 5-Helix are highly conserved in HIV-1, HIV-2, and simian immunodeficiency virus (SIV) (Fig. 4) .
As a potent, broad-spectrum inhibitor of viral entry, 5-Helix may serve as the basis for development of a new class of therapeutic agents against HIV-1 (24). Moreover, 5-Helix offers flexibility in the design of variants with better therapeutic characteristics. In principle, 5-Helix can be modified extensively to alter its immunogenic, antigenic, bioavailability, or inhibitory properties (25) . For example, the C-peptide binding site might be lengthened, shortened, or shifted in the gp41 sequence in order to optimize inhibitory potency by targeting different regions of the gp41 ectodomain.
It would be desirable to generate neutralizing antibodies that mimic the binding properties of 5-Helix. Unstructured C-peptide immunogens may not elicit broadly neutralizing antibodies, because the linear sequence of the gp41 C-peptide region is variable among different HIV-1 strains. The potent and broadspectrum inhibitory properties of 5-Helix suggest that an HIV-1 neutralizing antibody response might be generated using C-peptide analogs constrained in a helical conformation (i.e., as in the C-peptide region when it binds to 5-Helix).
Interestingly, the epitope for 2F5, a human monoclonal antibody directed against gp41 with broad neutralizing activity, is located immediately COOH-terminal to the C-peptide region targeted by 5-Helix (26) (27) (28) . It is unknown if 2F5 inhibits infection by interfering with trimer-of-hairpins formation. The conformation of the 2F5- (41) . The increase in ellipticity at 222 nm upon mixing indicates an interaction between the two species that increases the total helical content (corresponding to an additional 28 helical residues per associated C-peptide). bound epitope has recently been shown to exist in a hairpin turn (29) . Although antibodies elicited with fragments of gp41 containing this sequence do not possess significant virus-neutralizing activity (30, 31) , it is possible that constrained analogs ( perhaps with an adjacent helical C-peptide region) will lead to useful immunogens in efforts to develop an AIDS vaccine.
Alternatively, 5-Helix itself is a potential vaccine candidate. The possibility of eliciting an antibody response against transiently exposed conformations of proteins involved in HIV-1 fusion has been suggested (32). One possible well-defined target is the NH 2 -terminal coiled coil that is exposed in the prehairpin intermediate (18) . Speculatively, a 5-Helix-like intermediate may be exposed during the fusion process (33) and, in this case, antibodies directed against 5-Helix may inhibit viral entry.
Finally, structural (4) and computational (5) methods predict similar trimer-of-hairpins motifs for viruses in diverse families, including orthomyxoviridae, paramyxoviridae, filoviridae, and retroviridae. In some of these cases, inhibition of viral entry by peptides analogous to the C-peptides of gp41 has been demonstrated (34) (35) (36) . Thus, the 5-Helix design approach may offer a widely applicable strategy for inhibiting viral infections (37). (18)]. 25. Three potential obstacles to using 5-Helix as a therapeutic include proteolysis, renal filtration, and immune clearance. The stably folded core of 5-Helix is likely to be resistant to serum proteolysis, but it may be desirable to replace the flexible Gly/Ser peptide linker regions with sequences that are more protease-resistant. It should also be possible to generate 5-Helix variants with an increased molecular weight (by oligomerization or tethering to a large protein) to reduce the rate of kidney clearance. Immune reactiv
